Febuxostat (Teijin/Ipsen/TAP).
Febuxostat (TEI-6720; TMX-67), an oral non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), is being developed by Teijin, with licensees Ipsen and TAP Holdings, for the potential treatment of gout. In February 2005, it was reported that launch in Japan was expected to be delayed for several years due to the need for additional clinical trials; in May 2005, an EU filing was expected by the end of 2005.
Tomlinson
Brian
B
Division of Clinical Pharmacology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR China. btomlinson@cuhk.edu.hk
D000818:Animals; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000069465:Febuxostat; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D013844:Thiazoles; D000069465:Febuxostat; D014969:Xanthine Oxidase